
Tea Recalled Nationwide as FDA Sets Risk Level
Newsweek AI is in beta. Translations may contain inaccuracies—please refer to the original content.
A nationwide and cross-border recall of a popular relaxation tea, initiated after an ingredient mixup, has been designated by food inspectors as the second-highest risk level.
Herbalife International of America, which is based in Los Angeles, issued a voluntary recall of its Relaxation Tea on July 21. The recall affects 5,888 products sold online across the United States as well as in Mexico and Ecuador.
On August 6, the U.S. Food and Drug Administration (FDA) classified the recall as a Class II risk—a designation indicating products may cause temporary or medically reversible adverse health consequences.
No press release was issued and the FDA's classification alert did not state which ingredients had been mixed up. Newsweek has contacted Herbalife via email outside of regular office hours on Thursday.
Why It Matters
The FDA's decision to classify the recall as a Class II risk signals a significant, though not life-threatening, potential for harm. Class II recalls address situations where the use of a product could cause temporary or medically reversible adverse effects, or the probability of serious consequences is remote.
Stock image shows a woman smelling tea at sunset.
Stock image shows a woman smelling tea at sunset.
Getty Images
What To Know
The FDA said the recall stemmed from the use of an "incorrect ingredient received from supplier and used in manufacturing finished product Relaxation Tea."
The items' lot code, which is often found near the product's bar code, is: D925507J02. The expiration date is 04/11/2027, the FDA alert said.
Herbalife advised customers not to use the affected Relaxation Tea products.
FDA inspectors assign recalls one of three classifications—Class I, Class II, or Class III—to indicate the degree of hazard to people's health. The classifications are defined by the agency as:
Class I - a situation in which there is a reasonable probability that the use of, or exposure to, a violative product will cause serious adverse health consequences or death.
Class II - a situation in which use of, or exposure to, a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote.
Class III - a situation in which use of, or exposure to, a violative product is not likely to cause adverse health consequences.
What Happens Next
Consumers who purchased Herbalife Relaxation Tea are urged to check their packaging and discontinue use of any recalled units. Customers with affected products or safety concerns are advised to contact Herbalife's customer service or review the FDA's recall posting for detailed guidance.

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


Gizmodo
23 minutes ago
- Gizmodo
Handsoaps Recalled Over Bacteria That Can Cause Sepsis
Four brands of soap and skin products are being recalled by their manufacturer after they were discovered to potentially be contaminated with bacteria that can cause infections, and even lead to sepsis in immunosuppressed people, according to announcements from the FDA and DermaRite Industries. The products, DermaKleen, KleenFoam, DermaSarra, and PeriGiene, have been recalled nationwide in the U.S. and Puerto Rico over the bacteria Burkholderia cepacia (spelled as cepecia in the FDA press release), though the health agency didn't indicate how the contamination of the soaps may have occurred. The announcements from the FDA and DermaRite Industries also didn't state where the soaps and skin products were sold, though listings online suggest the soaps are often purchased by companies and institutions for use in public facilities. It's not clear how popular the products may be at physical retail stores where the average consumer might buy them for use in the home, though they are available at online retailers like Amazon. Neither DermaRite nor the FDA immediately responded to questions Monday. The FDA's description of the recalled products: 'In healthy individuals with minor skin lesions the use of the product will more likely result in local infections, whereas in immunocompromised individuals the infection is more likely to spread into blood stream leading to life-threatening sepsis,' the company said in a statement posted online. 'To date, DermaRite has not received any reports of adverse events related to this recall.' Consumers who believe they're experiencing issues after using these products are encouraged to contact their doctors. The lot numbers and expiration dates for the recalled products, according to DermaRite: Consumers who have questions about the recall are encouraged to call Mary Goldberg at DermaRite Industries at the number 973-569-9000 x104, Monday through Friday, from 9:00 am to 5:00 pm ET, according to the company's press release. The company can also be reached by email at: [email protected].


Medscape
23 minutes ago
- Medscape
FDA Okays Ketamine-Based Med for Post-Surgical Pain
The FDA has approved the racemic ketamine product known as KETARx (PharmaTher Holdings) for the treatment of post-surgical pain. 'This historic FDA approval…is a testament to years of dedicated development,' Fabio Chianelli, chairman and CEO of PharmaTher, said in a release. 'We remain steadfast in our mission to harness the pharmaceutical potential of ketamine for a range of mental health, neurological, and pain disorders,' he added. The company noted that it hopes to expand ketamine development into conditions such as Parkinson's disease, amyotrophic lateral sclerosis, depression, and complex regional pain syndrome. Its product has already received an orphan drug designation for the treatment of Rett syndrome. It added that, among psychedelic and 'psychedelic-adjacent' drugs, ketamine is the only one to be included on a list of Essential Medicines by the World Health Organization. The company initially announced that the FDA had set an approval goal date of April 2024 for KETARx. However, after 'minor deficiencies identified by Quality' were identified, the FDA assigned a new target date of October 2024. As reported by Medscape Medical News at the time, the FDA issued a complete response letter requesting additional information on the application. The final date of August 2025 was set after the company submitted the requested additional information.
Yahoo
37 minutes ago
- Yahoo
Nationwide recall alert: Soap products may cause sepsis, life-threatening infections
A voluntary recall has been initiated for certain soap products that could contain bacteria which can lead to 'life-threatening infections' including sepsis, according to the Food and Drug Administration (FDA). DermaRite Industries initiated the recall after discovering the products may be contaminated with Burkholderia Cepacia. This bacteria can cause local infections in healthy people with cuts, but it poses a serious risk to those with weakened immune systems, potentially leading to life-threatening sepsis if it enters the bloodstream. Exposure to Burkholderia Cepacia can lead to various symptoms from no symptoms at all to serious respiratory infections especially in patients with cystic fibrosis or other chronic lung disease, according to the Center for Disease Control (CDC). Other symptoms may include fever and fatigue. 'DermaRite has notified its distributors and customers by e-mail to immediately examine available inventory and destroy all affected products in accordance with each facility's process,' the statement reads. 'Consumers should contact their physician or healthcare provider if they have experienced any problems that may be related to taking or using this product.' The products being recalled are: DermaKleen, an over-the-counter healthcare antiseptic lotion soap with vitamin E DermaSarra, an over-the-counter gel used for temporary relief of itching associated with minor skin irritations due to dry skin, insect bites, detergents, sunburn KleenFoam, an over-the-counter foam soap with Aloe Vera used for handwashing PeriGiene, an over-the-counter antiseptic cleaner used for the perineal area The recalled products were distributed across the United States and in Puerto Rico, the FDA said. DermaRite had not received any reports of adverse events related to this recall. However, customers can report reactions or quality issues related to the products to FDA's MedWatch Adverse Event Reporting program either online or by mail or fax by downloading this form. More Business News Tobacco harvest in full swing at Wendolowski Farm in Hatfield (Photos) Popular regional bakery to close two Boston-area stores Say goodbye to your Hulu app - Disney is making a major change to how you'll stream in 2026 Walmart in Central Mass. looking to become supercenter Business Monday ETC: Aug. 11, 2025 Read the original article on MassLive. Solve the daily Crossword